Outlook Therapeutics, Inc. (OTLK) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Outlook Therapeutics, Inc. (OTLK) closed at USD 0.50 on 2026-10-15, a change of -60.9 % over the past year, with a market capitalization of USD 118.85M.

Outlook Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Outlook Therapeutics, Inc. key figures

Previous close

USD 0.50 (2026-10-15)

1-year change

-60.9 %

Market cap

USD 118.85M

Enterprise value

USD 126.04M

P/E ratio (trailing)

-0.70

P/E ratio (forward)

-4.07

EPS (trailing)

-0.70

EPS (forward)

-0.12

PEG ratio

n/a

Price to book

-8.72

Revenue growth

-99.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.10

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Outlook Therapeutics, Inc. and compare it with other stocks.